AR084695A1 - Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal - Google Patents

Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal

Info

Publication number
AR084695A1
AR084695A1 ARP110101932A ARP110101932A AR084695A1 AR 084695 A1 AR084695 A1 AR 084695A1 AR P110101932 A ARP110101932 A AR P110101932A AR P110101932 A ARP110101932 A AR P110101932A AR 084695 A1 AR084695 A1 AR 084695A1
Authority
AR
Argentina
Prior art keywords
medicinal
nucleus
porous matrix
insert device
lacrimal insert
Prior art date
Application number
ARP110101932A
Other languages
English (en)
Original Assignee
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care filed Critical Johnson & Johnson Vision Care
Publication of AR084695A1 publication Critical patent/AR084695A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00772Apparatus for restoration of tear ducts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente descripción se describen estructuras de núcleos de fármacos y métodos para núcleos de fármacos que contienen agentes terapéuticos. Estos núcleos pueden insertarse o fabricarse en los dispositivos de insertos lacrimales para tratar una variedad de enfermedades oculares al eludir agentes terapéuticos de acuerdo con un perfil de liberación determinado por la estructura y composición del núcleo medicinal.
ARP110101932A 2010-06-03 2011-06-03 Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal AR084695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35118510P 2010-06-03 2010-06-03

Publications (1)

Publication Number Publication Date
AR084695A1 true AR084695A1 (es) 2013-06-05

Family

ID=45065017

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101932A AR084695A1 (es) 2010-06-03 2011-06-03 Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal

Country Status (4)

Country Link
US (1) US20110301555A1 (es)
AR (1) AR084695A1 (es)
TW (1) TW201210581A (es)
WO (1) WO2011153284A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019139A1 (en) * 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US8911227B2 (en) 2012-01-11 2014-12-16 Johnson & Johnson Vision Care, Inc. Device for injection molding silicone rubber
RU2630601C2 (ru) * 2012-02-29 2017-09-11 Джонсон Энд Джонсон Вижн Кэа, Инк. Пробка для слезной точки с подключенной к источнику питания матрицей из удерживающих ячеек
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
EP2945686A4 (en) 2013-01-15 2016-08-31 Univ Colorado Regents APPARATUS FOR DRUG DELIVERY IN THE TISSUE SYSTEM
EP3380040B1 (en) 2015-11-23 2023-04-19 The Regents of The University of Colorado, A Body Corporate Lacrimal system for drug delivery
WO2017201255A1 (en) * 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
AU2007266475B2 (en) * 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
ES2533359T3 (es) * 2007-09-07 2015-04-09 Mati Therapeutics Inc. Núcleos de fármaco para liberación sostenida de agentes terapéuticos
TWI542338B (zh) * 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 用於活性劑之控制釋放的眼用裝置
TWI495459B (zh) * 2009-03-31 2015-08-11 Johnson & Johnson Vision Care 淚管塞(二)

Also Published As

Publication number Publication date
US20110301555A1 (en) 2011-12-08
TW201210581A (en) 2012-03-16
WO2011153284A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
AR084695A1 (es) Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal
AR081113A1 (es) Liberacion pulsatil de medicamentos desde un tapon de punctum
CO7240407A2 (es) Formas cristalinas de un modulador del receptor androgénico
AR078020A1 (es) Dispositivo de administracion pericorneal de farmacos
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
CR20150003A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huérfano rory
UY30883A1 (es) Tapones punctales y metodos de liberacion de agentes terapeuticos
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CO6450625A2 (es) Sistema intrauterino para uso en tratamiento médico
BR112015013137A2 (pt) moduladores do receptor órfão para retinóide do subtipo gama (ror-gama) para uso no tratamento de doenças autoimunes e inflamatórias
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CL2014000821A1 (es) Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer.
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
PE20142239A1 (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
CR20120493A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
BR112015006524A8 (pt) derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit)
AR084677A1 (es) Tapones lagrimales para la liberacion controlada de agentes terapeuticos
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
AR089990A1 (es) Dispositivo con nucleo y recubrimiento para la liberacion de farmacos
BR112013025769A2 (pt) inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos
GT201400288A (es) "compuestos de fenoxietil piperidina"

Legal Events

Date Code Title Description
FB Suspension of granting procedure